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Objective This study aimed to assess whether randomized controlled trials conducted in Africa with collaborators from outside Africa 
were more closely associated with health conditions that have a burden of disease that is of speciﬁc importance to Africa than with 
conditions of more general global importance or with conditions important to developed countries. We also assessed whether the 
source of funding inﬂuenced a study’s relevance to Africa.
Methods We compared randomized controlled trials performed in Africa that looked at diseases speciﬁcally relevant to Africa (as 
determined by burden of disease criteria) with trials classiﬁed as looking at diseases of global importance or diseases important to 
developed countries in order to assess differences in collaboration and funding.
Findings Of 520 trials assessed, 347 studied diseases that are speciﬁcally important to Africa; 99 studied globally important diseases 
and 74 studied diseases that are important to developed countries. The strongest independent predictor of whether a study was 
of speciﬁcally African or global importance was the corresponding author’s country of origin: African importance was negatively 
associated with a corresponding author being from South Africa (odds ratio (OR) = 0.04; 95% conﬁdence interval (CI) = 0.02–0.10) 
but there was little difference between corresponding authors from other African countries and corresponding authors from countries 
outside Africa. The importance of a study to Africa was independently associated with having more non-African authors (OR per 
author = 1.31; 95% CI = 1.08–1.58), fewer trial sites (OR per site = 0.69; 95% CI = 0.50–0.96), and reporting of funding (OR = 
2.14; 95% CI = 1.15–4.00). Similar patterns were present in the comparisons of trials studying diseases important to Africa versus 
those studying diseases important to developed countries with stronger associations overall. When funding was reported, private 
industry funding was negatively associated with African importance compared with global importance (OR = 0.31, P = 0.008 for 
African importance and OR = 0.51, P = 0.57 for importance for developed countries).
Conclusion The relevance to Africa of trials conducted in Africa was not adversely affected by collaboration with non-African 
researchers but funding from private industry was associated with a decreased emphasis on diseases relevant to Africa.
Keywords Research; Research support; International cooperation; Randomized controlled trials; Cost of illness; Endemic diseases; 
Africa (source: MeSH, NLM).
Mots clés Recherche; Aide recherche; Essai clinique randomisé; Coopération internationale; Coût maladie; Maladie endémique; 
Afrique (source: MeSH, INSERM).
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Introduction
Developing countries need to perform research, particularly on 
conditions and settings speciﬁc to their context, in order to 
maximize their yield from scarce health-care resources. Devel-
oping countries need support to conduct this research and to 
develop local research capacity. Increased research capacity in 
developing countries is believed to have beneﬁcial consequences 
for developed nations, for example in preventing the global 
spread of infectious agents (1, 2). The nature of the support 
from developed countries has, however, been debated, and the 
ethics of research collaboration between developed and develop-
ing nations have been widely discussed (3–5). Collaboration 
may sometimes be seen as reﬂecting a form of colonialism that 
serves the interests of foreign collaborators more than those of 
the host countries (6, 7). One means of improving the nature 
of the support from developed countries would be to allow local 
priorities to shape both basic and applied research studies (2, 
5, 6, 8). However, a regional consultative process conducted 
in Africa in preparation for the International Conference on 
Health Research for Development in 2000 concluded that in 
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the post-independence period priority setting has been hap-
hazard and determined by institutions or individuals instead of 
being based on the needs of the country or region (9).
The empirical relationship between international collabo-
ration and local relevance has not been quantitatively assessed. 
The relevance of interventions to a speciﬁc context is difﬁcult 
to deﬁne in operational terms. Frequently suggested criteria 
for determining research priorities include, in addition to the 
burden of disease existing from a target condition, the expected 
effectiveness and cost of an intervention, the probability of 
ﬁnding a solution, the effect on equity (i.e. the likely impact 
of the research on the poorer segments of the population), the 
feasibility of the research, its ethical acceptability, and the impact 
on capacity strengthening (10). Most of these criteria are dif-
ﬁcult to assess objectively, require specialist knowledge of a wide 
range of local conditions, and vary greatly depending on local 
conditions. Because an operational deﬁnition that incorporates 
all of these factors remains elusive, we limited our study to 
burden of disease as expressed in disability-adjusted life years 
(DALYs) for which widely accepted quantitative estimates by 
geographical region are available.
This study aimed to assess whether randomized con-
trolled trials conducted in Africa with collaborators from out-
side Africa were more closely associated with health conditions 
that have a burden of disease that is of speciﬁc importance to 
Africa than with conditions of more general global importance 
or with conditions important to developed countries. We also 
assessed whether the source of funding inﬂuenced the relevance 
of a study to Africa. This study received ethical approval from the 
Research Ethics Committee of the University of Cape Town.
Methods
Deﬁnitions
We compared trials performed in Africa that studied diseases 
speciﬁcally relevant to Africa with two groups of control trials: 
those that studied diseases of a more general global importance 
(globally relevant diseases) and those that studied diseases rel-
evant to developed countries.
We categorized diseases according to the size and distri-
bution of the burden of disease in 1990 in Africa, globally, and 
in established market economies (developed countries) (11) 
(Table 1). Diseases categorized as being speciﬁcally African dis-
eases were those that were important to Africa in both absolute 
and relative terms (burden of disease > 500 000 DALYs and 
burden of disease in sub-Saharan Africa > 50% of global bur-
den of disease). These diseases included HIV/AIDS, malaria, 
trypanosomiasis, schistosomiasis, onchocerciasis, and measles. 
Globally relevant diseases were those important to Africa in 
absolute terms but not in relative terms (burden of disease 
> 500 000 DALYs and burden of disease in sub-Saharan Africa 
< 15% of global burden). Altogether 19 categories of disease 
met these criteria (Table1). Diseases categorized as relevant to 
developed countries were those that were not important to 
Africa in either absolute or relative terms (burden of disease 
< 500 000 DALYs and burden in sub-Saharan Africa < 15% 
of global burden and burden of disease lower in Africa than 
in developed countries) but were important to developed 
countries (burden of disease > 200 000 DALYs). This group 
included 21 disease categories (Table 1). We used burden of dis-
ease estimates for 1990 because they may reﬂect health priorities 
at around the time that much of the research was performed. 
The categorization would have been similar using estimates of 
burden of disease for the year 2000.
Trial database
We identiﬁed randomized controlled trials from a database that 
had been developed for a previous study (12) and updated for 
this project. The database included randomized controlled tri-
als performed in sub-Saharan Africa involving human partici-
pants and targeting one or more health problems in the Global 
Burden of Disease taxonomy (11). We included multinational 
trials if some participants were recruited in sub-Saharan Africa. 
We excluded African trials enrolling non-local populations (e.g. 
tourists), trials addressing issues that could not be related to 
a disease or group of problems (such as health systems issues, 
pain and anaesthesia, general operative techniques, or smoking 
Table 1. Inclusion criteria for randomized controlled trials looking at diseases speciﬁcally important to Africa, globally 
important diseases and diseases important to developed countriesa
Characteristics Study category
 Diseases speciﬁcally  Globally important Diseases important to 
 important to Africa (n = 347) diseases (n = 99) developed countries (n = 74) 
Deﬁnition Burden of disease > 500 000 Burden of disease > 500 000 DALYs Burden of disease < 500 000 DALYs 
 DALYsb and burden of disease in and burden of disease in sub-Saharan and burden in sub-Saharan Africa < 15% 
 sub-Saharan Africa > 50% of Africa < 15% of global burden of global burden and burden of disease 
 global burden of disease  lower in Africa than in established market 
   economies; burden of disease in 
   developed countries > 200 000 DALYs
Disease categories  HIV/AIDS (58); malaria (189); Anaemia (33); liver cancer (4); Malignant neoplasms of oesophagus (6), 
(No. trials analysed) trypanosomiasis (2); diabetes (10); depression (8); stomach (1), lung (5), breast (5), ovary (2); 
 schistosomiasis (42);  epilepsy (3); alcohol dependence (2); leukaemia (1); psychoses (5); dementia (1); 
 onchocerciasis (31); measles (25) ischaemic heart disease (13);  Parkinson disease (2); multiple sclerosis (1); 
  cerebrovascular disease (1); chronic  drug dependence (1); panic disorder (3); 
  obstructive pulmonary disease (3); peptic ulcer (24); rheumatoid arthritis (6); 
  asthma (16); osteoarthritis (6)  dental caries (10); edentulism (1)
a  Trials involving multiple diseases in different case groups or control groups were excluded, except those involving anaemia in malaria; these were categorized as  
 being speciﬁcally important to Africa.
b  DALYs = disability-adjusted life years.
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cessation) and studies performed in northern Africa (part of 
the Middle Eastern Crescent region in the Global Burden of 
Disease estimates) (11). Letters, conference abstracts and sec-
ondary reports referring to methods described in earlier papers 
were not included.
To assemble the database we searched MEDLINE (to the 
end of 2002), the Cochrane Controlled Trials Register (Issue 
1, 2003), and the African Trials Register of the South African 
Cochrane Centre. The latter has been developed from seven 
international and African databases plus hand searching of 12 
African journals. Terms reﬂecting controlled trials were con-
jugated with “Africa”, “sub-Saharan Africa” and speciﬁc geo-
graphical locations.
Data extraction
In order to assess whether there were differences among trials 
categorized as being of importance to Africa, of global impor-
tance or importance to developed countries, we collected infor-
mation on the year of publication, the institutional afﬁliation 
(university, government, private industry, private non-industry, 
other) and country afﬁliation of the ﬁrst author and the cor-
responding author, the number of authors, the number and 
proportion of authors afﬁliated with non-African countries, 
whether the design was multicentre or single site, the num-
ber of sites, whether there was collaboration between two or 
more African countries, and whether any funding sources were 
reported.
We categorized authorship as African (including only 
sub-Saharan locations) and non-African. African authorship was 
further categorized as either South African (which accounted for 
approximately half of the trials) or other African. When authors 
had multiple afﬁliations that included a non-African institu-
tion, they were categorized as non-African. If the corresponding 
author was not identiﬁed, we assumed the ﬁrst author to be the 
corresponding author.
We categorized trials reporting funding sources accord-
ing to the country of origin of the funding body (South Africa, 
other African, non-African, or a combination of African and 
non-African) and type of funding institution (government, 
university, private industry, private non-industry, other, or a 
combination). We regarded foreign-based research councils with 
sites in Africa as non-African.
A single author (GHS) extracted data from the full 
report of each eligible trial. We assessed the reliability of data 
extraction by duplicate independent extraction of a 10% ran-
dom sample by a second author (VP). There was very good 
agreement for all items and κ coefﬁcients varied between 0.72 
and 1.00.
Statistical analysis
The main association of interest was whether collaboration 
with non-African authors or funding sources increased or 
decreased the odds of a trial studying a disease of importance 
to Africa. Assuming a 25% prevalence of collaboration with 
non-African sources in trials addressing speciﬁcally African 
health conditions (estimated from a small pilot study), 321 
cases and 107 controls (in each control group) were required 
to detect a twofold difference in the odds of a study being of 
importance to Africa, with 80% power at α = 0.05.
For each of the trial parameters listed above, we used lo-
gistic regression to estimate the odds of a study being of African 
importance versus global importance and African importance 
versus importance to developed countries. We then considered 
parameters with P < 0.10 in univariate analyses in a multivariate 
model, with backward elimination of variables according to 
likelihood ratio criteria in order to ﬁnd independent parameters 
associated with African importance. Analyses were conducted 
using SPSS statistical software version 11.0 (SPSS Inc., Chicago, 
IL). P-values are two-tailed.
Findings
Trials identiﬁed
Of 1297 trials in the database, 607 (46.8%) examined disease 
conditions deﬁned in this study. We excluded 83 (13.7%) of 
the 607, primarily because they were letters or conference 
abstracts. We could not locate full-text versions of a further 
four trials (0.7%). We analysed the remaining 520 trials. Of 
these, 347 studied diseases of speciﬁc interest to Africa; 99 
studied diseases of global importance; and 74 studied diseases 
important to developed countries (Table 1). Ten of the trials 
were performed in two countries; six were conducted in three 
countries; and three were conducted in four countries. Two 
trials in South Africa also had sites in Côte d’Ivoire and the 
United Republic of Tanzania.
The institutional and national afﬁliations of researchers 
and funding sources are shown in Table 2 and Table 3. The 
trials had a median of ﬁve authors (interquartile range = 3–7), 
with a median proportion of non-African authors of 37.5% 
(interquartile range = 0–75%) (data not shown). A total of 315 
trials (60.6%) reported funding sources. The majority (286; 
90.8%) had received funding from non-African sources; in 
256 (81.3%) cases there was no concomitant funding from 
African sources.
African importance compared with global 
importance
In univariate analyses, the trials that looked at diseases of im-
portance to Africa differed signiﬁcantly from those looking at 
diseases of global importance with respect to the country of 
origin and institutional afﬁliation of the ﬁrst and correspond-
ing authors (P < 0.001). Trials of African importance had been 
published more recently, had a larger number of authors, a 
larger number of non-African authors, and were more likely 
to report any source of funding (P < 0.001 for all). There was 
also a suggestion that trials of African importance involved 
fewer sites (P = 0.069). In multivariate modelling, the strongest 
independent predictor was the country of origin of the corre-
sponding author (P < 0.001) (Table 4). African importance was 
negatively associated with having a corresponding author from 
South Africa, but there was little difference between having 
corresponding authors from other African countries and non-
African countries. African importance was also independently 
more common when any source of funding was reported (P = 
0.017) and with increasing numbers of non-African authors 
(P = 0.006); it was less common as the number of study sites 
increased (P = 0.029).
African importance compared with developed 
countries
The trials that studied diseases important to Africa also differed 
signiﬁcantly from trials of diseases relevant to developed coun-
tries in terms of the country of origin and type of institutional 
afﬁliation of the ﬁrst and corresponding authors, as well as in 
the year of publication, the number of authors, the number of 
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non-African authors, the proportion of non-African authors 
and whether any source of funding was reported (P < 0.001 for 
all). The data also suggested that trials of African importance 
involved fewer study sites (P = 0.055) and were less likely to 
be multicentre investigations (P = 0.054).
In multivariate modelling, the strongest independent 
predictor of a trial’s importance to Africa was country of 
origin of the ﬁrst author (P < 0.001), with less importance to 
Africa occurring among trials with a ﬁrst author from South 
Africa, and with little difference between trials with authors 
from other African countries and those with non-African ﬁrst 
authors (Table 4). African importance was also independently 
more common when any source of funding was reported (P = 
0.001) as well as with increasing numbers of non-African au-
thors (P = 0.002); it was less common as the number of study 
sites increased (P = 0.003).
Overall, associations were stronger when trials of African 
importance were compared with trials of diseases important to 
developed countries than when trials of African importance were 
compared with trials of diseases of global importance (Table 4). 
For both comparisons, there was no signiﬁcant interaction be-
tween the country of origin of the corresponding author or 
ﬁrst author and the other parameters that were independently 
related to African importance. Thus, analyses excluding South 
African trials yielded similar results for these other parameters 
(data not shown).
Associations with funding
Analyses limited to studies with reported sources of funding 
yielded similar results. In addition, the source of funding was 
a signiﬁcant independent determinant of African importance 
Table 2. Randomized controlled trials by category of disease and characteristics of study
Characteristics of studies Category of disease studied by randomized controlled trialsa Total
 Speciﬁcally African Globally important Important to 
   developed countries 
First author’s afﬁliation
Government 144  (41) 18  (18) 2  (3) 164  (32)
University 180  (52) 70  (71) 63  (85) 313  (60)
Private industry 2  (1) 2  (2) 0   4  (1)
Other private 13  (4) 1  (1) 1  (1) 15  (3)
Other 6  (2) 7  (7) 8  (11) 21  (4)
Unknown 2  (1)  1  (1)  0  3  (1)
Corresponding author’s afﬁliation
Government 132  (38) 17  (17) 3  (4) 152  (29)
University 186  (54) 69  (70) 62  (84) 317  (61)
Private industry 8  (2) 5  (5) 1  (1) 14  (3)
Other private 13  (4) 1  (1) 1  (1) 15  (3)
Other 8  (2) 7  (7) 7  (9) 22  (4)
Unknown 0  0  0  0
Funding source
Government 143  (41) 10  (10) 7  (9) 160  (31)
University 3  (1) 2  (2) 0  5  (1)
Private industry 22  (6) 11  (11) 9  (12) 42  (8)
Other private 12  (4) 4  (4) 4  (5) 20  (4)
Other 0  0  0  0
Combination 70  (20) 14  (14) 4  (5) 88  (17)
Unknown 97  (28) 58  (59) 50  (68) 205  (39)
a  Figures in parentheses are percentages. Percentages may not sum to 100% due to rounding.
versus global importance. In the multivariate model we found 
that private industry funding was negatively associated with 
a study having African rather than global importance when 
we adjusted for the country of the corresponding author, the 
number of sites and the number of non-African authors (odds 
ratio = 0.31; 95% conﬁdence interval = 0.13–0.74; P = 0.008). 
There was little difference between trials that had both private 
industry funding and non-industry funding compared with 
trials that had only industry funding. A similar decrease in 
emphasis on diseases of African importance occurred with 
private industry funding when trials of African importance 
were compared with trials of diseases relevant to developed 
countries (multivariate odds ratio = 0.51) but was not statisti-
cally signiﬁcant (P = 0.57). This was probably the result of our 
limited sample size. (Funding sources were reported in only 24 
trials of diseases relevant to developed countries.)
Discussion
The ﬁndings of this study suggest that the relevance to Africa 
of trials conducted in Africa is not adversely affected by col-
laboration with non-African researchers. In fact, non-African 
authorship was far more strongly associated with relevance 
to Africa than was South African authorship. The reporting 
of funding was also associated with importance to Africa. In 
studies that reported their source of funding, the involvement 
of private industry was associated with a decreased emphasis 
on diseases relevant to Africa (in comparison with diseases that 
were important globally).
We focused on randomized controlled trials because they 
are considered to be the standard experimental design for gen-
erating reliable evidence in evaluating interventions for clinical 
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Table 3. National afﬁliations of researchers and funding sources
Study characteristic Category of disease studied by randomized controlled trialsa Total
 Speciﬁcally African Globally important Important to  
   developed countries 
First author’s afﬁliation
South Africa 8  (2) 49  (52) 59  (80) 116  (23)
Other African 129  (39) 22  (23) 8  (11) 159  (32)
Non-African 197  (59) 24  (25) 7  (9) 228  (45)
Corresponding author’s afﬁliation    
South Africa 8  (2) 50  (53) 58  (78) 116  (23)
Other African 102  (31) 21  (22) 8  (11) 131  (26)
Non-African 221  (67) 24  (25) 8  (11) 253  (51)
Funding source
South Africa 3  (1) 8  (8) 10  (14) 21  (4)
Other African 6  (2) 2  (2) 0  8  (2)
Non-African 218  (63) 27  (27) 11  (15) 256  (49)
Combination of African and 23  (7) 4  (4) 3  (4) 30  (6) 
non-African sources
Not reported 97  (28) 58  (59) 50  (68) 205  (39)
a  Figures in parentheses are percentages. Percentages may not sum to 100% due to rounding.
Table 4. Multivariate analysis of factors associated with 
African importance of research versus global importance or 
importance to developed countries
 Odds ratioa
Characteristic African African 
 importance  importance vs 
 vs global importance 
 importance to developed 
  countries
First author’s afﬁliation
South Africa NSb 1.00c
Other African NS 156  (38.9–626)
Non-Africand NS 179 (16.1–1988)
Corresponding author’s  
afﬁliation  
South Africa 0.04 (0.02–0.10) NS
Other African 1.00c NS
Non-Africand 0.82 (0.34–1.95) NS
Reported funding 2.14 (1.15–4.00) 8.84 (2.34–33.4)
No. of sites (per study)  0.69 (0.50–0.96) 0.34 (0.17–0.69)
No. of non-African 1.31 (1.08–1.58) 2.52 (1.40–4.55) 
authors (per study)
a  Figures in parentheses are 95% conﬁdence intervals.
b  NS = not signiﬁcant.
c  Reference value.
d  Non-African category also includes international afﬁliations.
practice, and their results are directly applicable to local health 
care. There have been systematic efforts to identify randomized 
controlled trials (13), and this facilitated our identiﬁcation of 
as complete a sample as possible. The low relevance to Africa 
of trials conducted by South African authors is disquieting. 
We performed a separate analysis of South African and other 
African authors a priori because we had previously suspected 
the differences that were conﬁrmed in this study. These differ-
ences may be due at least in part to the fact that the burden of 
disease in South African differs from that of other sub-Saharan 
countries. For example, malaria occurs in relatively limited geo-
graphical areas in South Africa; the full impact of HIV/AIDS 
was felt relatively late in its southward progression through 
Africa; and onchocerciasis and trypanosomiasis are rare. South 
African burden of disease data are not available for 1990, but 
by 2000 the only disease categorized as African in this study 
that featured in the top 20 causes of years of life lost was HIV/
AIDS (14). However, about 60% of the South African trials in 
our study were performed before the transition to democracy, 
and they could thus reﬂect earlier research priorities. The lag 
between the advent of democracy in 1994 and the publication 
of trials planned since then means that insufﬁcient trials are 
available to assess changes occurring since democracy.
The association between the importance of a trial to 
Africa with the reporting of funding may be due in part to 
the fact that smaller studies without formal funding may have 
reﬂected individual researchers’ personal priorities. It is also 
possible that funding from large non-proﬁt organizations, 
international sources and governments is likely to have been 
reported but smaller grants from private industry for smaller 
projects are more likely to have remained unreported. Generally, 
the use of African populations by pharmaceutical companies 
to obtain data for interventions to be marketed elsewhere or 
targeted towards more afﬂuent markets in Africa, could explain 
the negative association between industry funding and Afri-
can importance. Industry priorities seem to be guided by the 
eventual possibility of ﬁnding a global market (15) or at least 
afﬂuent markets in countries.
The limits of burden of disease as a marker for relevance 
have been discussed in the Introduction. An operational deﬁni-
tion of collaboration is also problematic, and the deﬁnition used 
in this study (institutional afﬁliation) is not fully informative. 
Further quantitative and qualitative research is needed to ex-
amine the objectives and nature of collaboration, such as who 
initiated the research and the criteria used to assess priorities. 
Health-systems research was excluded from our study if it did 
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Résumé
Essais contrôlés randomisés menés en Afrique : collaboration internationale, ﬁnancement et association 
avec la charge de morbidité
Objectif Cette étude vise à évaluer si les essais contrôlés 
randomisés effectués en Afrique avec des collaborateurs extérieurs 
à l’Afrique sont plus étroitement associés à des pathologies dont 
la charge de morbidité est particulièrement importante en Afrique 
qu’avec d’autres ayant une importance mondiale plus générale, 
ou qu’avec des pathologies importantes pour les pays développés. 
Nous avons également évalué si la source de ﬁnancement avait 
une inﬂuence sur l’utilité d’une étude pour l’Afrique.
Méthodes Nous avons comparé des essais contrôlés randomisés 
effectués en Afrique et s’intéressant à des maladies particulièrement 
importantes pour l’Afrique (sélectionnés selon des critères de 
charge de morbidité) à des essais considérés portant sur des 
maladies d’importance mondiale, ou sur des maladies importantes 
pour les pays développés, en vue d’évaluer les différences observées 
dans le niveau de collaboration et de ﬁnancement.
Résultats Sur les 520 essais évalués, 347 concernaient des 
maladies particulièrement importantes pour l’Afrique ; 99 des 
maladies importantes sur le plan mondial et 74 des maladies 
importantes pour les pays développés. Pour savoir si une étude est 
importante surtout pour l’Afrique ou au plan mondial, le facteur 
prédictif indépendant le plus fort est le pays d’origine de l’auteur : 
l’importance de l’étude pour l’Afrique est négativement associée 
à un auteur originaire d’Afrique du Sud (Odds ratio (OR) = 0,04, 
intervalle de conﬁance à 95 % (IC) = 0,02-0,10), mais on relève 
peu de différences entre des auteurs provenant d’autres pays 
africains et des auteurs de pays extérieurs à l’Afrique. L’importance 
d’une étude pour l’Afrique est indépendamment associée au fait 
d’avoir davantage d’auteurs non africains (OR par auteur = 1,31 ; 
IC à 95 % = 1,08 1,58), moins de sites d’essais (OR par site = 
0,69 ; IC à 95 % = 0,50 0,96) et une indication de ﬁnancement 
(OR = 2,14 ; IC à 95 % = 1,15 4,00). On a retrouvé les mêmes 
caractéristiques dans les comparaisons qui ont été faites entre les 
essais s’intéressant à des maladies importantes pour l’Afrique et 
ceux étudiant des maladies importantes pour les pays développés, 
les associations étant dans l’ensemble plus fortes. Lorsque 
l’origine des fonds est indiquée, le ﬁnancement par le secteur 
privé est négativement associé à l’importance pour l’Afrique par 
comparaison avec l’importance pour l’ensemble du monde (OR = 
0,31, p = 0,008 pour les maladies importantes pour l’Afrique et 
OR = 0,51, p = 0,57 pour les maladies importantes pour les pays 
développés).
Conclusion L’utilité pour l’Afrique des essais effectués sur ce 
continent n’a pas été négativement inﬂuencée par la collaboration 
avec des chercheurs non africains, mais le ﬁnancement privé est 
associé à une attention moindre portée aux maladies importantes 
pour l’Afrique.
Resumen
Colaboración internacional y fuentes de ﬁnanciación: relación con la carga de morbilidad en ensayos 
controlados aleatorizados en África
Objetivo El objeto de este estudio fue determinar si diversos 
ensayos controlados aleatorizados realizados en África con 
colaboradores de fuera del continente estaban más estrechamente 
relacionados con problemas de salud asociados a una carga de 
morbilidad de especial relevancia para África que con dolencias de 
importancia mundial más general o con enfermedades importantes 
para los países desarrollados. También evaluamos si la fuente de 
ﬁnanciación inﬂuía en la pertinencia del estudio para África.
Métodos Comparamos diversos ensayos controlados aleatorizados 
llevados a cabo en África y centrados en enfermedades 
especíﬁcamente pertinentes para África (según el criterio de la 
carga de morbilidad) con otros ensayos clasiﬁcados como centrados 
en enfermedades de importancia mundial o en afecciones 
relevantes para los países desarrollados, a ﬁn de evaluar las 
diferencias en cuanto a colaboración y ﬁnanciación.
Resultados De los 520 ensayos evaluados, 347 estudiaron 
enfermedades específicamente importantes para África; 99 
estudiaron enfermedades relevantes a nivel mundial, y 74 
estudiaron enfermedades importantes para los países desarrollados. 
La variable predictiva independiente más robusta respecto a si un 
estudio era de interés mundial o sólo para África fue el país de 
origen del autor al que debía enviarse la correspondencia: la 
relevancia para África estaba relacionada negativamente con el 
hecho de que un coautor encargado de la correspondencia fuera 
de Sudáfrica (razón de posibilidades (OR) = 0,04; intervalo de 
conﬁanza (IC) del 95% = 0,02–0,10), pero había poca diferencia 
entre los autores encargados de la correspondencia de otros países 
africanos y los autores con esa función de países no africanos. 
La importancia de un determinado estudio para África estaba 
relacionada de forma independiente con los siguientes factores: 
un mayor número de autores no africanos (OR por autor = 1,31; 
IC95% = 1,08–1,58), un menor número de sitios de ensayo 
(OR por sitio = 0,69; IC95% = 0,50–0,96), y la aportación de 
datos sobre la ﬁnanciación (OR = 2,14; IC95% = 1,15–4,00). Se 
not focus on a speciﬁc condition. Given the critical importance 
of health services in the delivery of effective interventions, 
further investigation should include a broader range of health-
services research.
We did not ﬁnd that collaboration with non-African 
researchers makes it less likely that research conducted in Africa 
will be relevant to Africa, but funding from industry and a lack 
of reporting of funding were associated with less of a chance 
of a study being relevant to Africa. This preliminary evidence 
suggests that extra-African research collaboration, using non-
industry-based funding, should continue to be fostered to sup-
port research in Africa. Improvements are needed to objectively 
assess the local importance of research projects to facilitate 
research. Further research should also examine the objectives 
and nature of collaborations.  O
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observaron pautas similares en las comparaciones de ensayos de 
estudio de enfermedades importantes para África frente a otros de 
estudio de enfermedades importantes para los países desarrollados, 
con relaciones más sólidas en general. Cuando se informaba sobre 
los fondos empleados, la ﬁnanciación por la industria privada 
estaba negativamente relacionada con la importancia para África 
en comparación con la importancia mundial (OR = 0,31, P = 0,008 
en el caso del interés para África, y OR = 0,51, P = 0,57 en el caso 
del interés para los países desarrollados).
Conclusión El interés para África de los ensayos realizados en 
este continente no se vio perjudicado por la colaboración de 
investigadores no africanos, pero la ﬁnanciación por la industria 
privada sí se asoció a un menor énfasis en las enfermedades 
pertinentes para África.
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